Design Therapeutics (DSGN)
NASDAQ:DSGN
US Market
Holding DSGN?
Track your performance easily

Design Therapeutics (DSGN) Ownership - Who Owns Design Therapeutics?

82 Followers

Design Therapeutics (DSGN) Ownership Overview

19.36%6.36%1.35%5.39%67.54%
19.36% Insiders
1.35% Other Institutional Investors
5.39% ETFs
67.54% Public Companies and
Individual Investors
The ownership structure of Design Therapeutics (DSGN) stock is a mix of institutional, retail, and individual investors. Approximately 13.09% of the company’s stock is owned by Institutional Investors, 19.36% is owned by Insiders, and 67.54% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value
Aug 12, 2024
xxxxxxxxxxxxx
$3463215
Mar 25, 2024
John Schmid
Director
xxxxxxxxxxxxx
$99659
Mar 25, 2024
xxxxxxxxxxxxx
$4862

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Jun 30, 2024
xxxxxxxxxxxxx
$5679234

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
6,526,476Insider11.53%43,140,006
4,217,627Insider7.45%27,878,514
1,695,294Institution2.99%11,205,893
1,368,011Institution2.42%9,042,553
1,232,739Institution2.18%8,148,405
1,103,406Institution1.95%7,293,514
705,900Institution1.25%4,665,999
359,435Institution0.63%2,375,865
275,438Institution0.49%1,820,645
238,799Institution0.42%1,578,461

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
1,103,406Institution1.95%7,293,514
705,900Institution1.25%4,665,999
359,435Institution0.63%2,375,865
275,438Institution0.49%1,820,645
238,799Institution0.42%1,578,461
224,300Institution0.40%1,482,623
150,003Institution0.26%991,520
143,703Institution0.25%949,877
74,915Institution0.13%495,188
54,200Institution0.10%358,262

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
860,488Institution1.52%5,687,826
800,901Institution1.41%4,308,847
399,505Institution0.71%2,149,337
296,089Institution0.52%1,957,148
141,300Institution0.25%823,779
143,698Institution0.25%773,095
72,378Institution0.13%478,419
68,399Institution0.12%398,766
55,015Institution0.10%295,981
37,412Institution0.07%247,293

FAQ

Who Owns Design Therapeutics (DSGN)?
According to the latest TipRanks data, approximately 1.35% of the company's stock is held by institutional investors, 19.36% is held by insiders, and 67.54% is held by retail investors.
    What percentage of Design Therapeutics (DSGN) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 1.35% of Design Therapeutics (DSGN) stock is held by institutional investors.
      What percentage of Design Therapeutics (DSGN) stock is held by retail investors?
      According to the latest TipRanks data, approximately 67.54% of Design Therapeutics (DSGN) stock is held by retail investors.
        Who owns the most shares of Design Therapeutics (DSGN)?
        Simeon George owns the most shares of Design Therapeutics (DSGN).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis